Maia Biotechnology, INC 8-K filings

MAIA Biotechnology reports significant clinical progress for its lead drug THIO, showing strong efficacy in lung cancer treatment and securing over $12 million in funding year-to-date.

MAIA Biotechnology reports strong efficacy data for its THIO therapy in non-small cell lung cancer, showing significant improvements over standard treatments.

MAIA Biotechnology released updated efficacy and safety data from its Phase 2 THIO-101 clinical trial, showing promising results for THIO in combination with cemiplimab for advanced non-small cell lung cancer patients.

MAIA Biotechnology successfully held its 2024 Annual Meeting, re-electing two directors and ratifying its independent auditor.

MAIA Biotechnology has increased the maximum offering price of its common stock under an existing agreement to $11.28 million.

MAIA Biotechnology has released a business presentation on its website, providing an overview of the company's activities.

MAIA Biotechnology has announced a $1 million private placement to fund research and development, including its THIO-101 trial for non-small cell lung cancer.

MAIA Biotechnology has increased the base salary and target bonus for executive Jeffrey Himmelreich, effective April 1, 2024.

MAIA Biotechnology has successfully raised $1.33 million through a private placement to fund research and development, particularly for its THIO-101 trial in non-small cell lung cancer.

MAIA Biotechnology has increased the maximum offering price of its common stock under an existing agreement to $4.95 million.

MAIA Biotechnology has entered into a securities purchase agreement for a private placement, raising approximately $2.92 million to fund research and development, including a pivotal trial for NSCLC.

MAIA Biotechnology reports a strong 38% overall response rate in a Phase 2 trial for its cancer drug THIO, and announces upcoming presentations at major cancer research conferences.

MAIA Biotechnology released a shareholder letter detailing progress on its immuno-oncology cancer treatment candidates, including the near completion of the THIO-101 Phase 2 trial.

MAIA Biotechnology has appointed Dr. Remus Vezan, a leading immuno-oncology scientist, to its Scientific Advisory Board.

MAIA Biotechnology has completed enrollment in its Phase 2 clinical trial for THIO-101 in non-small cell lung cancer, with topline data anticipated in the second half of 2024.

MAIA Biotechnology has entered into an agreement to sell up to $1.445 million of its common stock through an at-the-market offering.

MAIA Biotechnology has announced the publication of an international patent application for dinucleotide compounds targeting telomeres in cancer cells, potentially expanding the value of their cancer treatment platform.

MAIA Biotechnology reports promising interim results from its Phase 2 trial of THIO in non-small cell lung cancer, showing high disease control rates and outlining key clinical milestones for 2024.